Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18269655 | 1.00 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL2482829 | 0.94 | ALDH1A1 (0.59) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL985927 | 0.94 | ALDH1A1 (0.59) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL16060069 | 0.94 | ALDH1A1 (0.59) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL31356503 | 0.87 | — | — | |
| SCHEMBL1916142 | 0.87 | ALDH1A1 (0.49) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL2398393 | 0.87 | ALDH1A1 (0.49) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL2398531 | 0.87 | ALDH1A1 (0.49) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL28992188 | 0.85 | TP53 (0.49) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL12602871 | 0.84 | TP53 (0.47) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089788-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | claimed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| WO-2020127504-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-8236841-B2 | Fused heterocycle derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20090239853-A1 | Fused heterocycle derivative | KYOWA KIRIN CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-2070927-A1 | FUSED HETEROCYCLIC DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-7012083-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1072601-B1 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1077940-B1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6750231-B2 | SKIN DISORDERS; GASTROINTESTINAL DISORDERS | PFIZER INC | 2004-06-15 | — | — | US | disclosed |
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| US-6518282-B1 | Treatment of pruritic dermatoses including allergic dermatitis and atopy in animals and humans | PFIZER INC. | 2003-02-11 | — | — | US | disclosed |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | GIBSON STEPHEN PAUL (GB) | 2003-01-02 | — | — | US | disclosed |
| US-20020099214-A1 | Compounds useful in therapy | PFIZER INC. (US) | 2002-07-25 | — | — | US | disclosed |
| EP-1077940-A1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-1072594-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1072595-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1072601-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099214-A1 | Compounds useful in therapy | HRH2, ITCH, HRH4 | ALDH1A1 306/4885LMNA 4012/4885POLB 1964/4885 |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | HRH2, HRH4, HRH1 | ALDH1A1 895/4885LMNA 4687/4885POLB 4250/4885 |
| US-20090239853-A1 | Fused heterocycle derivative | NR5A2, CBR3, NR3C2 | ALDH1A1 2211/4885LMNA 3843/4885POLB 3438/4885 |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | ALDH1A1 857/4885LMNA 4133/4885POLB 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.